27 research outputs found
Penelitian Pemanfaatan Limbah Ekstraksi Kulit Kina
No full textKemungkinan pemanfaatan limbah kina yang diperoleh dari proses ekstraksi kulit pohon kina, Cinchona succirubra dan Chinchona ledgeriana, terutama pemanfaatannya sebagai bahan dasar pembuatan obat nyamuk bakar, arang briket dan papan partikel telah dipelajari.Hasil penelitian menunjukkan bahwa obat nyamuk bakar yang dihasilkan bermutu baik arang briket bermutu rendah dan untuk papan partikel sulit dibuat dari limbah kina
Efek Atorvastatin Terhadap LPL (Lipoprotein Lipase)Dan Profil Lipid Pada Pasien Anak Sindrom Nefrotik Refrakter Dengan Hiperlipidemia (Penelitian dilakukan di Poli Anak Nefrologi RSUD Dr. Soetomo)
Full text linkIntroduction: Hyperlipidemia occurs in SN caused by decrease level of lipoprotein lipase (LPL). LPL isan enzyme that is directly involved and a determinant rate in lipid metabolism through twocholesterol metabolism pathways. In previous study, lipid lowering agents haven’t alwaysgiven however in the literature, however, in the literature, statin administration remainscontroversial in the condition of refractory nephrotic syndrome. Objectives: To analyze the effect and the relationship of atorvastatin on lipid profiles (total cholesterol,LDL, TG, HDL) and LPL. Methods: This study has met the ethical eligibility with No. 1668/KEPK/XI/2019. A RCT doubleblind, pre and post test control group study of 31 children nephrotic syndrome refracter withhyperlipidemia patients divided into 2 groups. The first group (n = 18 patients) treated withplacebo and the other group (n = 13 patients) treated with atorvastatin. Observations carriedout for four weeks. The efficacy of therapy was measured by lipid profile and LPL.Results: We evaluated after 4 weeks, the total cholesterol and LDL from pre and post therapy of eachgroup show the significant differences (p<0,05). However, TG and HDL did not make asignificant difference. The LPL increased in the atorvastatin group but did not make asignificant difference. There is no significant difference between changes in lipid profile andchanges in LPL levels two group.Conclusion: Atorvastatin therapy significantly decreases total cholesterol and LDL but not in TG. Incontrast to total cholesterol, LDL and TG, administration of atorvastatin increases HDL andLPL. The relationship between LPL levels with total cholesterol, LDL, TG, and HDL levelshas not been proven.
1. Agrawal, S., Zaritsky, J., Fornoni, A. and Smoyer, W. 2018. Dyslipidemia in NephroticSyndrome: Mechanisms and Treatment. Nature Reviews Nephrology, vol 14, pp. 57-70.
2. Alatas, H., Trihono, PP. PP., Tambunan, T &Pardede, S. O. 2012. Konsensus TataLaksanaSindromNefrotikIdiopatikpadaAnak. Jakarta: BadanPenerbitIkatanDokterAnak Indonesia, pp. 1-36.
3. Anandkumar, S et al. 2016. Clinical Efficacy Study of Atorvastatin, Simvastatin andPravastatin in Hyperlipidemic Patients. International Journal of Pharmacy &Pharmaceutical Research, vol. 6 (4), pp. 523-530.
4. Andrade, Junior, M. 2018. Lipoprotein Lipase: A General Review. Insights in EnzymeResearch, vol.2 No.1:3, pp. 1-14.
5. Arshad, A. 2014. Comparison of Low-Dose Rosuvastatin with Atorvastatin in Lipid-Lowering Efficacy and Safety in a High-Risk Pakistani Cohort: An Open-LabelRandomized Trial. Journal of Lipids, pp. 1-5.
6. Astuti, K. D., Muryawan, M. H., Mellyana, O. 2015. Correlation Between Lipid Profile andC-reactive protein in Children with Nephrotic Syndrome. PaediatricaIndonesiana,vol. 55, No. 1, pp. 1-6.
7. Avis HJ, Vissers MN, Stein EA, et al. Asystematic review and meta-analysis of statintherapy in children with familial hypercholesterolemia. ArteriosclerThrombVascBiol. 2007;27(8):1803–1810
8. Avis, H. J., Vissers, M. N., Stein, E. A, et al. 2007. A Systematic Review and Meta Analysisof Statin Therapy in Children with Familial Hypercholesterolemia. Arteriosclerosis,Thrombosis, and Vascular Biology, vol. 27, no. 8, pp. 1803–1810.
9. B., S., B., M., & Joseph, N. 2019. Comparative Study of Lipid Profile Abnormalities in FirstEpisode and Relapse Cases of Childhood Nephrotic Syndrome. InternationalJournal of Contemporary Pediatrics, vol 3, pp. 1297-1300.
10. Balakumar, P., &Mahadevan, N. 2012. Interplay between statins and PPARs in improvingcardiovascular outcomes: a double-edged sword?. British journal of pharmacology,165 (2), pp. 373–379.
11. Baxter, J. H., Goodman, H. C., Allen, J. C. 1987. Effects of Infusions of Serum Albumin onSerum Lipids and Lipoprotein in Nephrosis. The Journal of Clinical Investigation,vol. 40 (3), pp. 490-498.
12. Bayly, G. 2014. Lipids and Disorders of Lipoprotein Metabolism. Clinical Biochemistry :Metabolic and Clinical Aspects, ppp.702-736.
13. Belay, B., Belamarich, PP., & Tom-Revzon, C. 2007. The Use of Statins in Pediatrics:Knowledge Base, Limitations, and Future Directions. Pediatrics, vol. 119 (2), pp.370-380.
14. Bobkova, I., Chebotareva, N., Kozlovskaya, L. and Shilov, E. 2016. Edema in RenalDiseases – Current View on Pathogenesis. Nephrology Point of Care, vol. 2 (1), pp.1-9.
15. Boullart, A. C. I., J. de Graff, Stalenhoef, A. F. 2012. Serum Trygliceride and Risk ofCardiovascular Disease. Biochimica et BiophysicaActa - Molecular and CellBiology of Lipids, vol. 1821 (5), pp. 867-875.
16. Bushara, H. M., Ahmed, E. M. 2006. Hyperlipidemia in Children with Nephrotic Syndromein Khartoum State. Faculty of Medicine. Islamic University.
17. Chan, M. K., Persaud, J.W., Varghese, Z., Moorhead, J. 1984. Post heparin hepatic andlipoprotein lipase activator in nephrotic syndrome. Australian and New ZealandJournal of Medicine, vol. 14 (6), pp. 841-847.
18. Clee SM, Bissada N, Miao F, Miao L, Marais AD, Henderson HE, Steures P et al. 2000.Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. JLipid Res, 41(4), pp.521-531
19. Cohen, E. PP., Lippold, C. 2019. Nephrotic Syndrome. Accessed in 08/24/2019https://emedicine.medscape.com/article/244631.
20. David Alpers. 2008. Role of Lipoprotein Lipase in triglyceride metabolism: potentialtherapeutic target. Future Lipidology, vol 4, pp. 385-397.
21. Davidson, M. H. 2011. A systematic review of bile acid sequestrant therapy in children withfamilial hypercholesterolemia. Journal of Clinical Lipidology, vol 5 (2), pp. 76–81.
22. Ding, W. and Saleem, M. 2012. Current Concepts of the Podocyte in Nephrotic Syndrome.Kidney Research and Clinical Practice, vol 2, pp.87-93.
23. Downie, M., Gallibois, C., Parekh, R. and Noone, D. 2017. Nephrotic Syndrome in Infantsand Children: Pathophysiology and Management. Paediatrics and InternationalChild Health, vol 37, pp. 248-258.
24. Dragana N, Andreea Corina, Peter. P. Toth, LubnaHammad&Manfredi Rizzo. 2019.Choosing an ideal pharmacotherapeutic strategy for dyslipidemia in children. ExpertOpinion on Pharmacotherapy, 20(3), pp.241-244. https://doi.org/10.1080/14656566.2018.1552942
25. Eiland, L. S., Luttrell, PP. K. 2010. Use of Statins for Dyslipidemia in the PediatricPopulation. The Journal of Pediatric Pharmacology and Theraupetics, vol 15 (3),pp. 160–172.
26. Endo, K., Miyashita, Y., Saiki, A., Oyama, T. 2004. Atorvastatin and Pravastatin ElevatedPre-heparin Lipoprotein Lipase Mass of Type 2 Diabetes with Hypercholesterolemia.Journal of Atherosclerosis and Thrombosis, vol 11, pp. 341–347.
27. Feingold KR, Grunfeld C. Cholesterol Lowering Drugs. 2018. Endotext [Internet]. Availablefrom: https://www.ncbi.nlm.nih.gov/books/NBK395573/
28. Filippas-Ntekouan S, Elisaf M S. 2016. Pathophysiological Mechanisms of Dyslipidemia inPatients with Nephrotic Syndrome: A Fresh Look. Hellenic Journal Atherosclerosis,vol 7 (3), pp. 102-110.
29. Floege, J. and Feehally, J. 2010. Introduction to Glomerular Disease. ComprehensiveClinical Nephrology, pp.193-207.
30. Florentin M., Liberopoulos E., Elisaf M. 2008. Ezetimibe-associated adverse effects: whatthe clinician needs to know. International Journal of Clinical Practice, vol. 62 (1),pp. 88–96.
31. Garcia-Rios A, Nikolic D, Perez-Martinez P, et al. 2014. LDL and HDL Subfractions,Dysfunctional HDL: treatment options. Current Pharmaceutical Design, vol 20 (40),pp. 6249–6255.
32. Girona, J., Rodríguez-Borjabad, C., Ibarretxe, D., Heras, M., Amigo, N., Feliu, A., et al.2018. Plasma inducible degrader of the LDLR, soluble low-density lipoproteinreceptor, and proprotein convertase subtilisin/kexin type 9 levels as potentialbiomarkers of familial hypercholesterolemia in children. Journal of ClinicalLipidology, vol 12, ppp.211-218.
33. Gupta, S., Pepper, R., Ashman, N. and Walsh, S. 2019. Nephrotic Syndrome: OedemaFormation and Its Treatment with Diuretics. Frontiers in Physiology, vol 9, pp. 1-10.
34. Hari, PP., Khandelwal, PP., Satpathy, A., Hari, S., Thergaonkar, R., Lakshmy, R., Sinha, A.andBagga, A. 2018. Effect Of Atorvastatin On Dyslipidemia And Carotid Intima-Media Thickness In Children With Refractory Nephrotic Syndrome: A RandomizedControlled Trial. Pediatric Nephrology, vol 33, pp.2299-2309.
35. Heller, F. R., Descampsa, O. S., Hondekijna, J. C., Desager J. PP. 2000. European Journalof Internal Medicine, vol 11, pp.33-38.
36. Huang, Y., &Mahley, R. 2014. Apolipoprotein E: Structure and function in lipidmetabolism, neurobiology, and Alzheimer's diseases. Neurobiology Of Disease, vol72, pp. 3-12.
37. Johnson, R., Floege, J. and Feehally, J. 2019. Introduction to Glomerular Disease.Comprehensive Clinical Nephrology 6th Ed. New York: Hayle Medical.
38. Kaneko, K., Tsuji, S., Kimata, T. et al. 2015. Pathogenesis of childhood idiopathic nephroticsyndrome: a paradigm shift from T-cells to podocytes. World J Pediatr, Vol. 11,pp.21–28. https://doi.org/10.1007/s12519-015-0003-9.
39. Karam I., Yang Y. J and Li J. Y. 2017. Hyperlipidemia Background and Progress. SMAtherosclerosis Journal, vol 1 (1), pp. 1003.
40. Kari, J. A., Tashkandi, M., Medhat, A. M., Khoja, S. O., Ramadan, K. S. 2012. Lipoprotein (a) and Other Dyslipidemia in Saudi Children with Nephrotic Syndrome (SSNS andSRNS). Journal of Health Science, vol 2, pp. 57-63.
41. Katzung, B., Kruidering-Hall, M. and Trevor, A. 2019. Katzung& Trevor'spharmacology, 12th edition, New York: McGraw-Hill Education, pp. 359-361.Kaysen, G. & de Sain-van der Velden, M. 1999. New insights into lipid metabolism in thenephrotic syndrome. Kidney International, vol. 56, pp. S18-S21.
42. Kluger, AY, Tecson, KM, Sudhakaran, Sudhakaran, S, Zhang, J et al. 2019. Statin Update:Intolerance, Benefit, and Beyond. Hypertension Journal.https://doi.org/10.15713/ins.johtn.0141
43. Kocher, O. & Krieger, M. 2009. Role of the adaptor protein PDZK1 in controlling the HDLreceptor SR-BI. Current Opinion in Lipidology, vol 20 (3), pp.236-241.
44. Kocher, O., Yesilaltay, A., Shen, C., Zhang, S., Daniels, K., Pal, R., et al. 2008. InfluenceOf PDZK1 On Lipoprotein Metabolism And Atherosclerosis. Biochimica etBiophysicaActa - Molecular Basis of Disease, vol 1782, pp. 310-316.
45. Kong, X., Yuan, H., Fan, J., Li, Z., Wu, T. and Jiang, L. 2013. Lipid-Lowering Agents ForNephrotic Syndrome. Cochrane Database of Systematic Reviews, vol 10 (12), pp.1-38.
46. Kusters, D. M., Caceres M, Coll M, et al. 2015. Efficacy and Safety of EzetimibeMonotherapy in Children with Heterozygous Familial or NonfamilialHypercholesterolemia. The Journal of Pediatrics, vol 166 (6), pp. 1377–1378.
47. Langslet, G., Breazna, A. and Drogari, E. 2016. a 3-year Study of Atorvastatin in Childrenand Adolescents with Heterozygous Familial Hypercholesterolemia. Journal ofClinical Lipidology, vol 10 (5), pp.1153-1162.
48. Lim J, Lee J, Kim J, Hwang Y, Kim T, Lim S et al. 2017. Comparison of World HealthOrganization and Asia-Pacific body mass index classifications in COPD patients.International Journal of Chronic Obstructive Pulmonary Disease, Vol. 12,pp.2465-2475. https://doi.org/10.2147/COPD.S141295
49. Linton MRF, Yancey PG, Davies SS, et al. 2019. The Role of Lipids and Lipoproteins inAtherosclerosis. Available from: https://www.ncbi.nlm.nih.gov/books/NBK343489/
50. Liu, S. M &Vaziri, N. D., 2013. Role of PCSK9 and IDOL in the Pathogenesis of AcquiredLDL Receptor Deficiency and Hypercholesterolemia in Nephrotic Syndrome.Nephrology Dialysis Transplantation, Volume 29 (3), pp. 538-543.
51. McCrindle, B. W., Ose, L, Marais, A. D. 2003. Efficacy and safety of atorvastatin in childrenand adolescents with familial hypercholesterolemia or severe hyperlipidemia: amulticenter, randomized, placebo-controlled trial. The Journal of Pediatrics; vol 143(1), pp. 74–80.
52. Miyashita Y, Shirai K, Itoh Y, Sasaki H, Totsuka M, Murano T, and Watanabe H. 2002.Low Lipoprotein Lipase Mass in Preheparin Serum of Type 2 Diabetes MellitusPatients and its Recovery with Insulin Therapy. Diabetes Res ClinPract, 56,pp.181-187
53. Moumita,. G., Laskar, A. 2016. MYLIP/IDOL In Regulation To Cholesterol Metabolism.Indian Journal of Ethnophytopharmaceuticals, vol 2 (1), pp.33-36
54. Niaudet, PP., Matto, T. K., Kim, M. S. 2018. Etiology, Clinical Manifestations, andDiagnosis Of Nephrotic Syndrome In Children. UpToDate
55. Noone, D., Iijima, K. and Parekh, R. 2018. Idiopathic Nephrotic Syndrome in Children. TheLancet, vol 392 (10141), pp.61-74.
56. Nourbakhsh, N and Mak, R. 2017. Steroid-Resistant Nephrotic Syndrome: Past and CurrentPerspectives. Pediatric Health, Medicine and Therapeutics, vol 8, pp. 29-37.
57. Nozue, T. 2017. Lipid Lowering Therapy and Circulating PCSK9 Concentration. Journalof Atherosclerosis and Thrombosis, vol 24, pp. 895-907.
58. Oesterle, A., Laufs, U. and Liao, J. 2017. Pleiotropic Effects of Statins on the CardiovascularSystem. Circulation Research, vol 120, pp. 229-243.
59. O'Gorman C, S., O'Neill M, B., Conwell L, S. 2010. Considering statins for cholesterolreductionin children if lifestyle and diet changes do not improve their health: a reviewof the risks and benefits. Vasc Health Risk Manag, 20 (7), pp. 1-14.
60. Olivecrona, G. 2016. Role of lipoprotein lipase in lipid metabolism. Current Opinion inLipidology, vol 2, pp. 233-241.
61. Paola M, Moreno R, Garcia P. 2011. Characteristics of idiopathic nephrotic syndrome at anunusual age in a tertiary-level pediatric hospital in Guadalajara, Jalisco, Mexico. BolMed Hosp Infant Mex, Vol. 68, pp.250-256
62. Pottel H, Hoste L, Delanaye P. 2014. Abnormal glomerular filtration rate in children,adolescents and young adults starts below 75 mL/min/1.73 m2. PediatricNephrology, 30(5), pp.821-828. https://doi.org/10.1007/s00467-014-3002-5
63. Pramana, PD., Mayetti, Kadri, H.. 2013. Hubunganantara Proteinuria danHipoalbuminemiapadaAnakdenganSindromNefrotik yang Dirawat di RSUP Dr. M. Djamil Padangperiode 2009-2012. JurnalKesehatanAndalas, Vol. 2, pp.1-2.
64. Querfeld U, Kohl B, Fiehn W, Minor T, Michalk D, Schaarer K, Muller-Wiefel DE. 1999.Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome.Report of a prospective uncontrolled multicenter study. Pediatric Nephrology, vol 13(1), pp. 7-12.
65. Rader, D. J., Hobbs, H. H. 2015. Harrison’s Principles of Internal Medicine, 19th edition,pp. 3215-3219.
66. Radhakrishnan, J., Glassock, R. J., Rovin, B. H. & Lam, A. Q., 2018. Lipid Abnormalitiesin Nephrotic Syndrome. UptoDate.
67. Rinsho, N. 2004. Refractory nephrotic syndrome. PubMed, vol 62 (10), pp. 1794-1799.
68. Rosenson, R. S., Freeman, M. W., Saperia, G. M. 2018. Statins: Actions, Side Effects, andAdministration. UptoDate.
69. SareGülfemÖzlü, GülayDemircin, NazanTökmeci, AysunÇaltık Yılmaz, ÖzlemAydoğ,Mehmet Bülbül& Ayşe Öner. 2015. Long-term prognosis of idiopathic nephroticsyndrome in children, Renal Failure, 37:4, pp.672-677.https://doi.org/10.3109/0886022X.2015.1010940
70. Sasaki M, Terao Y, Ayaori M, et al. 2014. Hepatic overexpression of idol increasescirculating protein convertase subtilisin/kexin type 9 in mice and hamsters via dualmechanisms: sterol regulatory element-binding protein 2 and lowdensity lipoproteinreceptor-dependent pathways. Arteriosclerosis Thrombosis and Vascular Biology,vol 34 (6), pp. 1171–1178.
71. Schachter, M. 2004. Chemical, pharmacokinetic and pharmacodynamics properties ofstatins: an update. Fundamental & Clinical Pharmacology, Vol. 19 (1), pp. 117-125.
72. Schachter, M. 2004. Chemical, pharmacokinetic and pharmacodynamic properties of statins:an update. Blackwell Publishing Fundamental & Clinical Pharmacology, Vol. 19,pp.117-125.
73. Schilling, J. A., Moreau, D., Robinson, J. M et al. 2005. Pathophysiology a 2-in-1Reference for Nurses. Philadelphia: Lippincott Williams & Wilkins, pp. 544-546.
74. Schneck, D. W., Birmingham, B. K., Zalikowski, J. A., et al. 2004. The effect of gemfibrozilon the pharmacokinetics of rosuvastatin. Clinical Pharmacology & Therapeutics,vol 75, pp. 455-463.
75. Schwartz G, Work D. 2009. Measurement and Estimation of GFR in Children andAdolescents. Clinical Journal of the American Society of Nephrology, Vol. 4(11),pp.1832-1843. https;//doi.org/10.2215/CJN.01640309.
76. Siddall, E. &Radhakrishnan, J. 2012. The pathophysiology of edema formation in thenephrotic syndrome. Kidney International, vol 82, pp. 635-642.
77. Sorrentino, V., Fouchier, S., Motazacker, M., Nelson, J., Defesche, J., Dallinga-Thie, G.,Kastelein, J., KeesHovingh, G. and Zelcer, N. 2013. Identification of a loss-offunctioninducible degrader of the low-density lipoprotein receptor variant inindividuals with low circulating low-density lipoprotein. European Heart Journal,vol 34, pp. 1292-1297.
78. Srinivasa, R.K., Prasad, T., Mohanta G.PP., Manna PP.K., 2011. An overview of statins ashypolipidemic drugs. International Journal of Pharmaceutical Sciences and DrugResearch, vol. 3, pp.178-183.
79. Stancu, C. and Sima, A. 2001. Statins: mechanism of action and effects. Journal of Cellularand Molecular Medicine, vol 5, pp. 378-387.
80. Takahashi, S., Hiromura, K., Tsukida, M., Ohishi, Y., et al. 2013. Nephrotic Syndromecaused by Immune-Mediated Acquired LCAT Deficiency. Journal of the AmericanSociety of Nephrology, vol 24, pp. 1305-1312.
81. Tapia C, Bashir K. 2019. Nephrotic Syndrome. StatPearls [Internet]. StatPearls Publishing.Available from: https://www.ncbi.nlm.nih.gov/books/NBK470444/
82. Tkachenko, O. O., Scherier, R., Shchekochikhin, D. 2013. The Nephrotic Syndrome:Pathogenesis and Treatment of Edema Formation and Secondary Complications.Pediatric Nephrology, vol 29 (7), pp. 1159-1167.
83. Vaziri, N. D. 2016. Disorders Of Lipid Metabolism In Nephrotic Syndrome: MechanismsAnd Consequences. Kidney International, vol 90 (1), pp. 41-52.
84. Vaziri, N. D., Liang, K. 2002. Upregulation of AcylcoenzymeA : CholesterolAcyltransferase (ACAT) in Nephrotic Syndrome. Kidney International, vol. 61, pp.1769–1775.
85. Vidianty J, Pardede S, Hendarto A, Akib A. 2010. Obesity in Children with Frequent Relapseand Steroid Dependent Nephrotic Syndrome. PaediatricaIndonesiana, Vol. 50(3),pp.139. https://doi.org//10.14238/pi50.3.2010.139-43
86. Viswanath, D. 2013. Nephrotic Syndrome in Children. Journal of Indian Academy of OralMedicine and Radiology, vol 25 (1), pp.18-23.
87. Wang, C. S., Hartsuck, J., &McConathy, W. J. 1992. Structure and Fuctional Properties ofLipoprotein Lipase. Biochimica et BiophysicaActa-Lipids and Lipid metabolism,vol 1123 (1), pp. 1-17.
88. Wang, H., Garruti, G., Liu, M., Portincasa, PP. & Wang, D. 2017. Cholesterol andLipoprotein Metabolism and Atherosclerosis: Recent Advances in ReverseCholesterol Transport. Annals of Hepatology, vol 16, pp. S27-S42.
89. Wang, X., Wang, L., Tu, Y., & Zhang, Y. 2018. Traditional Chinese Medicine for RefractoryNephrotic Syndrome: Strategies and Promising Treatments. Evidence-BasedComplementary and Alternative Medicine, vol 2018, pp. 1-11.
90. Weissel, RC. 2002. Body Mass Index as an Indicator of Obesity. Asia Pacific J ClinNutr,Vol. 11, pp.S681–S684.
91. Wirya WIGN. 2002. SindromNefrotik. In: Alatas H, Tambunan T, Trihono PP,(penyunting). Buku ajar nefrologianakjilid 2. Jakarta: BalaiPenerbit FKUI, pp. 382-419.
92. Yang J, Kim T, Koo B, Park B, Park J. 1999. Change of plasma lipoproteins by heparinreleasedlipoprotein lipase. Experimental & Molecular Medicine, 31(2), pp.60-64.
93. Yoon, J. 2014. Dyslipidemia in Children and Adolescents: When and How to Diagnose andTreat?.Pediatric Gastroenterology, Hepatology& Nutrition, vol 17 (2), pp. 85-92.
94. Zhang, C. P et al. 2015. IDOL, Inducible Degrader Of Low-Density Lipoprotein Receptor,Serves As A Potential Therapeutic Target For Dyslipidemia. Medical Hypotheses,vol 86, pp. 138-142
95. Zhang, L., Reue, K., Fong, L., Young, S. and Tontonoz, PP. 2012. Feedback Regulation ofCholesterol Uptake by the LXR–IDOL–LDLR Axis. Arteriosclerosis, Thrombosis,and Vascular Biology, vol 32 (11), pp. 2541-2546.
96. Zillerudo G, Sung, L., Freeundich, M., Strauss, J. 1984. Persistence of serum lipidabnormalities in chidlren with idiopathic nephrotic syndrome. The Journal ofPediatrics, vol 104 (1), pp. 61-65
Euclid preparation. Simulations and nonlinearities beyond CDM. 2. Results from non-standard simulations
Full text linkInternational audienceThe Euclid mission will measure cosmological parameters with unprecedented precision. To distinguish between cosmological models, it is essential to generate realistic mock observables from cosmological simulations that were run in both the standard -cold-dark-matter (CDM) paradigm and in many non-standard models beyond CDM. We present the scientific results from a suite of cosmological N-body simulations using non-standard models including dynamical dark energy, k-essence, interacting dark energy, modified gravity, massive neutrinos, and primordial non-Gaussianities. We investigate how these models affect the large-scale-structure formation and evolution in addition to providing synthetic observables that can be used to test and constrain these models with Euclid data. We developed a custom pipeline based on the Rockstar halo finder and the nbodykit large-scale structure toolkit to analyse the particle output of non-standard simulations and generate mock observables such as halo and void catalogues, mass density fields, and power spectra in a consistent way. We compare these observables with those from the standard CDM model and quantify the deviations. We find that non-standard cosmological models can leave significant imprints on the synthetic observables that we have generated. Our results demonstrate that non-standard cosmological N-body simulations provide valuable insights into the physics of dark energy and dark matter, which is essential to maximising the scientific return of Euclid
Euclid. I. Overview of the Euclid mission
Full text linkInternational audienceThe current standard model of cosmology successfully describes a variety of measurements, but the nature of its main ingredients, dark matter and dark energy, remains unknown. Euclid is a medium-class mission in the Cosmic Vision 2015-2025 programme of the European Space Agency (ESA) that will provide high-resolution optical imaging, as well as near-infrared imaging and spectroscopy, over about 14,000 deg^2 of extragalactic sky. In addition to accurate weak lensing and clustering measurements that probe structure formation over half of the age of the Universe, its primary probes for cosmology, these exquisite data will enable a wide range of science. This paper provides a high-level overview of the mission, summarising the survey characteristics, the various data-processing steps, and data products. We also highlight the main science objectives and expected performance
Euclid. V. The Flagship galaxy mock catalogue: a comprehensive simulation for the Euclid mission
Full text linkInternational audienceWe present the Flagship galaxy mock, a simulated catalogue of billions of galaxies designed to support the scientific exploitation of the Euclid mission. Euclid is a medium-class mission of the European Space Agency optimised to determine the properties of dark matter and dark energy on the largest scales of the Universe. It probes structure formation over more than 10 billion years primarily from the combination of weak gravitational lensing and galaxy clustering data. The breath of Euclid's data will also foster a wide variety of scientific analyses. The Flagship simulation was developed to provide a realistic approximation to the galaxies that will be observed by Euclid and used in its scientific analyses. We ran a state-of-the-art N-body simulation with four trillion particles, producing a lightcone on the fly. From the dark matter particles, we produced a catalogue of 16 billion haloes in one octant of the sky in the lightcone up to redshift z=3. We then populated these haloes with mock galaxies using a halo occupation distribution and abundance matching approach, calibrating the free parameters of the galaxy mock against observed correlations and other basic galaxy properties. Modelled galaxy properties include luminosity and flux in several bands, redshifts, positions and velocities, spectral energy distributions, shapes and sizes, stellar masses, star formation rates, metallicities, emission line fluxes, and lensing properties. We selected a final sample of 3.4 billion galaxies with a magnitude cut of H_E<26, where we are complete. We have performed a comprehensive set of validation tests to check the similarity to observational data and theoretical models. In particular, our catalogue is able to closely reproduce the main characteristics of the weak lensing and galaxy clustering samples to be used in the mission's main cosmological analysis. (abridged
Euclid preparation. XLI. Galaxy power spectrum modelling in real space
Full text linkInternational audienceWe investigate the accuracy of the perturbative galaxy bias expansion in view of the forthcoming analysis of the Euclid spectroscopic galaxy samples. We compare the performance of an Eulerian galaxy bias expansion, using state-of-art prescriptions from the effective field theory of large-scale structure (EFTofLSS), against a hybrid approach based on Lagrangian perturbation theory and high-resolution simulations. These models are benchmarked against comoving snapshots of the Flagship I N-body simulation at , which have been populated with H galaxies leading to catalogues of millions of objects within a volume of about . Our analysis suggests that both models can be used to provide a robust inference of the parameters in the redshift range under consideration, with comparable constraining power. We additionally determine the range of validity of the EFTofLSS model in terms of scale cuts and model degrees of freedom. From these tests, it emerges that the standard third-order Eulerian bias expansion can accurately describe the full shape of the real-space galaxy power spectrum up to the maximum wavenumber , even with a measurement precision well below the percent level. In particular, this is true for a configuration with six free nuisance parameters, including local and non-local bias parameters, a matter counterterm, and a correction to the shot-noise contribution. Fixing either tidal bias parameters to physically-motivated relations still leads to unbiased cosmological constraints. We finally repeat our analysis assuming a volume that matches the expected footprint of Euclid, but without considering observational effects, as purity and completeness, showing that we can get consistent cosmological constraints over this range of scales and redshifts
Technology responsiveness for digital preservation: a model
No full textDigital preservation may be defined as the cumulative actions undertaken by an organisation or individual to ensure that digital content is usable across generations of information technology. As technological change occurs, the digital preservation community must detect relevant technology developments, determine their implications for preserving digital content, and develop timely and appropriate responses to take full advantage of progress and minimize obsolescence.
This thesis discusses the results of an investigation of technology responsiveness for digital preservation. The research produced a technology response model that defines the roles, functions, and content component for technology responsiveness. The model built on the results of an exploration of the nature and meaning of technological change and an evaluation of existing technology responses that might be adapted for digital preservation. The development of the model followed the six-step process defined by constructive research methodology, an approach that is most commonly used in information technology research and that is extensible to digital preservation research.
This thesis defines the term technology responsiveness as the ability to develop continually effective responses to ongoing technological change through iterative monitoring, assessment, and response using the technology response model for digital preservation
BioTIME 2.0 : Expanding and Improving a Database of Biodiversity Time Series
Full text linkPeer reviewe
Social-environmental drivers inform strategic management of coral reefs in the Anthropocene
Full text linkWithout drastic efforts to reduce carbon emissions and mitigate globalized stressors, tropical coral reefs are in jeopardy. Strategic conservation and management requires identification of the environmental and socioeconomic factors driving the persistence of scleractinian coral assemblages—the foundation species of coral reef ecosystems. Here, we compiled coral abundance data from 2,584 Indo-Pacific reefs to evaluate the influence of 21 climate, social and environmental drivers on the ecology of reef coral assemblages. Higher abundances of framework-building corals were typically associated with: weaker thermal disturbances and longer intervals for potential recovery; slower human population growth; reduced access by human settlements and markets; and less nearby agriculture. We therefore propose a framework of three management strategies (protect, recover or transform) by considering: (1) if reefs were above or below a proposed threshold of >10% cover of the coral taxa important for structural complexity and carbonate production; and (2) reef exposure to severe thermal stress during the 2014–2017 global coral bleaching event. Our findings can guide urgent management efforts for coral reefs, by identifying key threats across multiple scales and strategic policy priorities that might sustain a network of functioning reefs in the Indo-Pacific to avoid ecosystem collapse
The ecomics of ecosystems and biodiversity: scoping the scale
No full textThe G8 decided in March 2007 to initiate a “Review on the economics of biodiversity loss”, in the so called Potsdam Initiative: 'In a global study we will initiate the process of analysing the global economic benefit of biological diversity, the costs of the loss of biodiversity and the failure to take protective measures versus the costs of effective conservation. The study is being supported by the European Commission (together with the European Environmental Agency and in cooperation with the German Government. “The objective of the current study is to provide a coherent overview of existing scientific knowledge upon which to base the economics of the Review, and to propose a coherent global programme of scientific work, both for Phase 2 (consolidation) and to enable more robust future iterations of the Review beyond 2010.
